Incorporating Tumor Biology to Select Patients for the Omission of Radiation Therapy

Surg Oncol Clin N Am. 2023 Oct;32(4):725-732. doi: 10.1016/j.soc.2023.05.006. Epub 2023 Jun 9.ABSTRACTAlthough adjuvant breast radiotherapy has long been a universal component of breast conservation therapy (BCT), it is now clear that "breast cancer" is a broad class of many disparate diseases with varying natural histories and risk profiles. In turn, some breast conservation patients enjoy exceedingly favorable outcomes following surgery alone. Ongoing trials seek to identify such low-risk patient populations, hypothesizing that some may safely forego radiotherapy. Whereas prior-generation trials focused on clinicopathologic features for risk stratification, contemporary studies are employing molecular biomarkers to identify those patients who are unlikely to benefit significantly from radiotherapy.PMID:37714639 | DOI:10.1016/j.soc.2023.05.006
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research